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MS-based applications in the clinic are 
expanding, and the recent “BreathPrint” 
study suggests its reach could extend into 
asthma classification (1). Of seven tested 
volatile organic compounds (VOCs), five 
were confirmed as biomarkers capable of 
classifying asthma to the same degree 
as currently used tests, which typically 
examine induced sputum and/or blood 
and exhaled nitric oxide (FeNO).
Here, we speak with Jean-François 
(Jef) Focant to find out more.
Why are new markers needed for 
asthma phenotyping?
When a patient is diagnosed with 
asthma, it is necessary to accurately 
determine the inflammatory phenotype 
to guide therapeutic approaches. There is 
not a single fully accurate test that can 
do this. Nowadays, clinicians use 
induced sputum (mucus from the 
lower airways) for inflammatory 
phenotyping. The cells present 
in the sputum are counted and 
characterized on the basis of 
their morphology. Based on 
the number of neutrophilic 
and eosinophil ic cel ls 
present in the sputum, 
two thresholds have been 
establ ished, and four 
phenotypes have been 
proposed ,  inc lud ing 
eosinophilic asthma (high 
number of eosinophilic 
cells) and neutrophilic 
asthma (high number of 
neutrophilic cells). However, 
sputum analysis is not available 
in most medica l centers. 
Sputum cell count can be 
supported or replaced by 
blood eosinophil count 
or fractional exhaled 
nitr ic ox ide (FeNO) 
measurements, but the 
accuracy of these tests 
can still be improved. 
Ne w ma rk e r s  a r e 
needed to support 
cl inicians in their 
phenotype diagnosis 
– ideally using a non-
invasive approach, 
given that a patient’s 
phenotype may change 
over time and require repeated tests.
What analytical methods did you use 
– and what were the results?
The BreathPrint study was accomplished 
in two phases. First, a set of seven 
potential asthma phenotyping biomarker 
VOCs were selected through a discovery 
study (276 patients) at Maastricht 
University in the Netherlands, using GC-
Time-of-Flight MS (GC-TOFMS). 
Second, we performed an independent 
validation study (245 new patients) in 
Liège using GC×GC-high-resolution 
TOFMS (GC×GC-HR-TOFMS). We 
confirmed five biomarkers that can be 
used to phenotype asthma with the same 
degree of accuracy as induced sputum, 
blood eosinophil count, and surrogate 
FeNO breathing tests. Furthermore, 
when blood eosinophil count, FeNO 
measurement, and biomarker VOCs 
were used together, an unprecedented 
classif ication model performance 
was obtained for eosinophilic asthma 
diagnosis. In future, complex mixtures 
of biomarker VOCs could eventually 
improve asthma phenotyping and could 
become a new gold standard, next to 
induced sputum cell count.
What were the main challenges  
– and your solutions?
Exhaled breath analysis is challenging in 
itself. Moreover, large-scale GC×GC-
HR-TOFMS studies are not common 
and the analytical framework needed to 
be designed. First, we had to be sure that 
our method of sampling the breath would 
allow us to isolate putative biomarkers 
despite being present at potentially low 
levels amongst non-relevant exogenous 
molecules, while maintaining a simple 
sample collection procedure. 
In addit ion, every step of the 
analytical workflow had to be optimized 
to produce high-quality data matrices to 
ease data processing as much as possible. 
Compound identification was confirmed 
using the two retention times, specific 
electronic ionization mass spectra, 
and HR-MS information. Instrument 
performance (for example, linearity and 
limit of detection) was evaluated for 
the different targets. Sample batches 
included quality control standards 
to account for possible instrumental 
variations and to ensure data integrity. 
The same care was applied in the 
optimization of the preprocessing 
and processing workflow to ensure 
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process. The classification models were 
built using random forest – a machine-
learning algorithm based on a forest of 
decision trees. Each model was based on 
bootstrapping cross-validation and data 
splitting between training and test sets.
What are the next steps for this research?
So far, we have been using GC×GC-
HR-TOFMS to confirm a set of five 
biomarkers using a targeted approach. 
What we are doing now is to reconsider 
the entire validation set (245 patients) 
using a non-targeted approach. As 
a matter of fact, we have created a 
composite image template containing 
more than 700 analytes that can be 
used to highlight subtle differences 
in the breath fingerprint of asthmatic 
patients. Such a non-superv ised 
volatilomic approach has the potential 
to link specific VOC profiles to subsets 
of patients based on a number of factors, 
including current medication, food 
habits, environment, toxicant exposure, 
and so on. These VOC fingerprints 
certainly hold a significant amount of 
information that could be revealed… 
From an analytical point of view, because 
of the availability of HR-MS data, we 
could also investigate other data-mining 
approaches, such as Kendrick Mass 
Defect classifications.
What impact do you expect the work 
could have in the clinic?
We hope that this unique approach will 
be positively received by the medical 
community, which desperately needs 
better ways of phenotyping asthma. 
We have already been duplicating 
selected sample measurements with 
selected-ion flow-tube MS analyses to 
evaluate the possibility of transposing 
the method to simpler instrumentation 
that could be used directly in hospitals 
for the screening of the five biomarkers 
molecules – or to create pattern-based 
patient classification methods. Direct 
sample introduction into selected-ion 
flow-tube MS would also help eliminate 
the need for the transfer procedures prior 
to measurement. Such a move would 
be the logical next step in the line of 
making this VOC approach usable by 
practitioners in the hospital environment 
– and perhaps even in doctor’s offices.
Do you expect such applications of 
MS to become more commonplace?
Time will tell. But I am quite sure that 
there is room for MS-based diagnostic 
strategies that rely on VOC patterns in 
the medical field. Will we see GC×GC-
HR-TOFMS instruments blooming 
in hospitals? I’m not sure at this point. 
Will medical staff domesticate these 
complex instruments? I guess it depends 
if the trend goes in the direction of target 
analysis of validated biomarkers or towards 
exhaustive breathprinting of patients. In 
any case, current instrumentation in the 
GC×GC-MS domain will definitely play 
some role in medical diagnosis based on 
volatilomics in the future –  and it will go 
far beyond breath analysis…
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